Bone Biologics receives Nasdaq minimum bid price deficiency notice, has until March 9, 2027
Bone Biologics said on September 10, 2026 that it received a Nasdaq letter because its stock closed below $1 per share for 30 consecutive business days. The company has 180 days, until March 9, 2027, to regain compliance, and it plans to seek stockholder approval for a reverse stock split at its upcoming annual meeting. The notice has no immediate effect on the stock's listing, but a failure to regain compliance could lead to delisting proceedings.
Key points
- Nasdaq letter dated September 10, 2026 cites closing bid price below $1 per share for the last 30 consecutive business days
- Compliance period runs 180 calendar days, until March 9, 2027
- Regaining compliance requires a closing bid price of at least $1 for 10 consecutive business days
- Company intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.